Level Up Your MRD Testing: Leveraging Standardized & Sensitive AML Assessments

During this webinar, Dr. Tony Sanchez will speak about the etiology of AML, the prognostic significance of known AML mutations, and the importance of NGS-based MRD monitoring. Joshua Wemmer will discuss the FLT3 ITD MRD and NPM1 MRD Assay performance and how to leverage Dockerized software for objective MRD testing.

Topics:

• Describe how FLT3 and NPM1 mutations impact AML prognosis and treatment decisions
• Discuss the significance of MRD assay sensitivity, insertion size and micro-clones
• Understand the role of standardized RUO assays and the importance of objective RUO software

Speaker:

• Tony Sanchez, M.D.   
• Josh Wemmer, M.S.